Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $8.00 at Wedbush

Sutro Biopharma (NASDAQ:STRO) had its price objective cut by equities research analysts at Wedbush from $12.00 to $8.00 in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 62.27% from the stock’s current price. Wedbush also issued estimates for Sutro Biopharma’s Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.76) EPS.

A number of other analysts have also recently issued reports on STRO. HC Wainwright reduced their price objective on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday. JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Tuesday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sutro Biopharma currently has a consensus rating of “Buy” and an average price target of $13.71.

Sutro Biopharma Price Performance

STRO stock opened at $4.93 on Tuesday. The firm has a market capitalization of $300.48 million, a P/E ratio of -2.77 and a beta of 0.95. Sutro Biopharma has a 52-week low of $2.01 and a 52-week high of $6.11. The company’s 50 day simple moving average is $4.47 and its 200-day simple moving average is $3.77.

Insider Activity

In other news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the completion of the transaction, the insider now owns 12,803 shares in the company, valued at $64,015. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Sutro Biopharma by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,890,000 shares of the company’s stock valued at $12,398,000 after acquiring an additional 21,238 shares during the last quarter. Virtu Financial LLC bought a new stake in Sutro Biopharma during the fourth quarter worth about $72,000. Exome Asset Management LLC acquired a new position in shares of Sutro Biopharma during the 4th quarter worth about $659,000. Barclays PLC raised its stake in Sutro Biopharma by 111.0% in the fourth quarter. Barclays PLC now owns 132,059 shares of the company’s stock valued at $566,000 after buying an additional 69,480 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of Sutro Biopharma by 1.7% in the fourth quarter. Nuveen Asset Management LLC now owns 215,728 shares of the company’s stock valued at $925,000 after buying an additional 3,583 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.